6-thioguanine can cause serious liver injury in inflammatory bowel disease patients
Authors:
- Marla C DubinskyMarla C Dubinsky
- Eric A VasiliauskasEVEric A Vasiliauskas
- Hardeep SinghHSHardeep Singh
- Maria T AbreuMaria T Abreu
- Kostas A PapadakisKPKostas A Papadakis
- Tram TranTTTram Tran
- Paul MartinPMPaul Martin
- John M VierlingJVJohn M Vierling
- Stephen A GellerSGStephen A Geller
- Stephan R TarganSTStephan R Targan
- Fred F PoordadFPFred F Poordad
- 1 August 2003
- journal article
- Published by Elsevier in Gastroenterology
- Vol. 125 (2) , 298-303
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Thioguanine: A Potential Alternate Thiopurine for Ibd Patients Allergic To 6-Mercaptopurine Or AzathioprineAmerican Journal of Gastroenterology, 2003
- An Open-Label Pilot Study Using Thioguanine as a Therapeutic Alternative in Crohn's Disease Patients Resistant to 6-Mercaptopurine TherapyInflammatory Bowel Diseases, 2001
- #672 Oral 6-thioguanine (TG) causes relatively mild and reversible hepatic venoocclusive disease (VOD)Journal of Pediatric Hematology/Oncology, 1998
- Azathioprine and 6-Mercaptopurine in Crohn DiseaseAnnals of Internal Medicine, 1995
- Thioguanine used in maintenance therapy of chronic myeloid leukaemia causes non‐cirrhotic portal hypertension. RESULTS FROM MRC CML II TRIAL COMPARING BUSULPHAN WITH BUSULPHAN AND THIOGUANINEBritish Journal of Haematology, 1991
- Idiopathic portal hypertension associated with cytotoxic drugs.Journal of Clinical Pathology, 1990
- OESOPHAGEAL VARICES ASSOCIATED WITH BUSULPHAN-THIOGUANINE COMBINATION THERAPY FOR CHRONIC MYELOID LEUKAEMIAThe Lancet, 1987
- Nodular Regenerative Hyperplasia of the Liver in Hematologic DisordersMedicine, 1980